Browse News
Filter News
Found 209 articles
-
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
3/8/2024
Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California.
-
Kymera Therapeutics to Participate in Upcoming March 2024 Investor Conferences
2/28/2024
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, announced that the Company will participate in fireside chats at the following upcoming investor events.
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
2/22/2024
Kymera Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights and updates on its pipeline of protein degraders.
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
2/15/2024
Kymera Therapeutics, Inc. will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.
-
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
1/31/2024
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.
-
Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways
1/24/2024
Synnovation Therapeutics launched today with a $102 million Series A.
-
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
1/17/2024
INVO and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024.
-
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
1/9/2024
Kymera Therapeutics, Inc. today announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
-
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
1/9/2024
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.
-
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
1/5/2024
Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced the pricing of its underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
-
Kymera Therapeutics Announces Proposed Public Offering - Jan 04, 2024
1/4/2024
Kymera Therapeutics, Inc. announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
-
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team
1/4/2024
Scorpion Therapeutics, Inc. announced leadership changes intended to position the Company for its next phase of growth, including the appointment of Adam Friedman, M.D., Ph.D., as Chief Executive Officer.
-
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
1/4/2024
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today will share an overview of its strategy to build the industry leading immunology pipeline of oral degrader medicines that target validated pathways and demonstrate efficacy comparable to biologic therapies.
-
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
1/2/2024
Kymera Therapeutics, Inc. today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET.
-
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
12/13/2023
Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced the appointment of Jeff Albers as Chair of the Board and Allison Luo, M.D., to the Board of Directors.
-
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4Company to provide update on its emerging pipeline of high-value immunology programs
12/13/2023
Kymera Therapeutics, Inc. today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET.
-
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
12/11/2023
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, shared new data from its ongoing KT-333 Phase 1 trial.
-
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
12/7/2023
Kymera Therapeutics, Inc. today announced that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in AD, generating a $15 million milestone payment under its collaboration with Sanofi.
-
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
11/28/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA interference (RNAi) therapeutics manufacturing landscape on Friday, December 8, 2023, at 10:00 am ET.
-
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
11/13/2023
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that results from the positive Phase 1 clinical trial from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader, were published in Nature Medicine.